VT3989 not checked

Vivace Therapeutics, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“• 100 mg orally once daily for 2 weeks on treatment followed by 2 weeks off treatment (2W/2W) in each 4-week cycle”In the company’s words, NCT07824986 on ClinicalTrials.gov
Tested for
Pleural Mesothelioma (2 trials), Mesothelioma (2 trials), Solid Tumor, Adult, NSCLC, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer, Epithelioid Hemangioendothelioma (EHE), Adenoma and 4 more
Main trialPhase 3
“This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.”In the company’s words, NCT07824986 on ClinicalTrials.gov

Other drugs for Pleural Mesothelioma

All 28 drugs for Pleural Mesothelioma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 1 May 2028 A Phase 3 Trial in Advanced Epithelioid Mesothelioma
Phase 1/2Recruiting 2 Nov 2029 Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VT3989

Following is part of Solo: you see every change to VT3989 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in